GSK plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Luke Victor Miels
- Full Time Employees
- 68,629
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 980 Great West Road Brentford United Kingdom TW8 9GS
- IPO Date
- Mar 28, 1980
- CIK
- 0001131399
- Website
- gsk.com
- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
GSK plc (GSK) M&A Call Transcript
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
Thistle Resources intersects broad gold mineralization at Middle River
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Abacus Global Management launches AI lifespan modeling platform
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
5 Things to Know Before the Stock Market Opens
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
Nuvalent Stock Soars on $10.6 Billion GSK Buyout
GSK Agrees $10.6 Billion Nuvalent Deal at 40% Premium
Breakfast News: CRM & ACN Lead Wave Of M&A Action
GSK's $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
Cancer-Drug Stock Jumps 39% on $10.6 Billion GSK Deal. Why It's a Surprise Move.
GSK falls as £8bn takeover of Nuvalent is largest deal in a decade